Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455411 | 1.00 | GSK3B (0.33) | GSK3BALDH1A1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL5943229 | 0.86 | C1S (0.35) | MAPTXDHKMT2AGAAMEN1 | |
| SCHEMBL5943225 | 0.86 | C1S (0.35) | MAPTXDHKMT2AGAAMEN1 | |
| SCHEMBL5354872 | 0.85 | DRD4 (0.36) | ALDH1A1SMN1; SMN2MAPTRAB9AXDH | |
| SCHEMBL5354877 | 0.85 | DRD4 (0.36) | ALDH1A1SMN1; SMN2MAPTRAB9AXDH | |
| SCHEMBL5215255 | 0.84 | GPBAR1 (0.36) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5215249 | 0.84 | GPBAR1 (0.36) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL5452890 | 0.83 | NOTUM (0.31) | — | |
| SCHEMBL5452893 | 0.83 | NOTUM (0.31) | — | |
| SCHEMBL5351150 | 0.82 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2MAPTXDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060293344-A1 | Therapeutic Compounds | BOYD F L | 2006-12-28 | — | — | US | disclosed |
| US-7153855-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050049260-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-20050049259-A1 | Theraopeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1366048-B1 | PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049259-A1 | Theraopeutic compounds | PCSK9, FOLH1, EPHA2 | GSK3B 934/4885ALDH1A1 1417/4885SMN1; SMN2 422/4885 |
| US-20060293344-A1 | Therapeutic Compounds | PCSK9, ABCB1, ABCB11 | GSK3B 1284/4885ALDH1A1 232/4885SMN1; SMN2 1226/4885 |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | GSK3B 2943/4885ALDH1A1 881/4885SMN1; SMN2 3864/4885 |
| US-20050049260-A1 | Therapeutic compounds | ABCB1, PCSK9, ABCB11 | GSK3B 1209/4885ALDH1A1 224/4885SMN1; SMN2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.